| __timestamp | CRISPR Therapeutics AG | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 381287000 |
| Thursday, January 1, 2015 | 13403000 | 452612000 |
| Friday, January 1, 2016 | 31056000 | 316800000 |
| Sunday, January 1, 2017 | 35845000 | 330100000 |
| Monday, January 1, 2018 | 48294000 | 265800000 |
| Tuesday, January 1, 2019 | 63488000 | 336200000 |
| Wednesday, January 1, 2020 | 88208000 | 423900000 |
| Friday, January 1, 2021 | 102802000 | 467000000 |
| Saturday, January 1, 2022 | 102464000 | 487000000 |
| Sunday, January 1, 2023 | 76162000 | 477100000 |
| Monday, January 1, 2024 | 72977000 |
Data in motion
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, United Therapeutics Corporation and CRISPR Therapeutics AG have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, United Therapeutics consistently maintained higher SG&A expenses, peaking at nearly 487% more than CRISPR Therapeutics in 2022. This reflects their expansive operational scale and robust market presence. Meanwhile, CRISPR Therapeutics, a pioneer in gene-editing technology, has seen a steady rise in SG&A, with a notable 20-fold increase from 2014 to 2021, indicating their aggressive growth and market penetration strategy. As the biotech sector continues to innovate, understanding these financial dynamics offers valuable insights into the strategic priorities of these industry leaders.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.